#1 Clinical Trials Search in Europe

Pramipexole Dihydrochloride Monohydrate

Pramipexole Dihydrochloride Monohydrate, specifically its R(+) form, is being studied as a potential treatment for Amyotrophic Lateral Sclerosis (ALS). This article explores several clinical trials investigating the drug’s effectiveness, safety, and impact on ALS progression. These studies aim to provide valuable insights into how this experimental neuroprotective drug might benefit patients with early-stage ALS.

Table of Contents

What is R(+) Pramipexole Dihydrochloride Monohydrate?

R(+) Pramipexole Dihydrochloride Monohydrate, also referred to as R(+)PPX, is an experimental drug being studied for its potential neuroprotective properties[1]. This medication is currently under investigation as a possible treatment for Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord[2].

R(+) Pramipexole in ALS Treatment

R(+)PPX is being explored as a potential treatment for ALS due to its antioxidant properties. Antioxidants are substances that can protect cells from damage caused by harmful molecules called free radicals. In the context of ALS, R(+)PPX is particularly interesting because it can concentrate in the brain and mitochondria (the energy-producing structures in cells)[2]. This characteristic may make it effective in combating the oxidative stress that is believed to play a role in the progression of ALS.

Clinical Trials and Research

Several clinical trials have been conducted to evaluate the effectiveness and safety of R(+)PPX in treating ALS. These studies aim to determine how well the drug works and what dosages might be most beneficial. Some key aspects of these trials include:

  • Open-label extension study: This type of study allows patients who have participated in earlier clinical trials to continue receiving the experimental drug[1]. This can provide valuable long-term data on the drug’s effects and safety.
  • Futility study: A study designed to determine if R(+)PPX can slow down the progression of ALS in its early stages. The researchers are looking to see if the drug can decrease the rate of decline in ALS symptoms by at least 40%[2].
  • High-dose treatment study: This research focuses on how R(+)PPX behaves in the body (pharmacokinetics) and its effects on oxidative stress in ALS patients[3].

Dosage and Administration

The dosage of R(+)PPX varies across different clinical trials. Here are some examples of the dosages being studied:

  • 60 mg per day, taken as 20 mg three times daily orally[1]
  • 30 mg per day, taken as 10 mg three times daily orally[2]
  • 300 mg per day, taken as 100 mg three times daily orally[3]

It’s important to note that these dosages are part of clinical trials and are not yet approved for general use. The appropriate dosage, if the drug is eventually approved, would be determined based on the results of these and future studies.

Potential Benefits and Outcomes

The clinical trials are designed to measure several outcomes that could indicate the effectiveness of R(+)PPX in treating ALS. These include:

  1. ALS Functional Rating Scale (ALS-FRS or ALS-FRSr): This is a scale used to measure the progression of ALS symptoms. Researchers are looking to see if R(+)PPX can slow down the decline in this score[2].
  2. Forced Vital Capacity (FVC): This is a measure of lung function, which is often affected in ALS patients[2].
  3. Hand dynamometry: This test measures hand strength, which can be an indicator of disease progression in ALS[2].
  4. Biochemical markers of oxidative stress: These are indicators in the body that can show whether the drug is having its intended effect on reducing oxidative damage[3].

By monitoring these outcomes, researchers hope to determine whether R(+)PPX can effectively slow down the progression of ALS and improve the quality of life for patients with this challenging disease.

Trial Name Drug Dosage Primary Outcome Duration Key Features
NCT00596115 20 mg three times daily Not specified Not specified Open-label extension study for ALS patients from earlier protocols
NCT00140218 10 mg three times daily ALS-FRSr score 9 months (3-month lead-in, 6-month treatment) Futility design Phase II study for early ALS
NCT00600873 100 mg three times daily Decline in ALSFRS score 6 months Focuses on pharmacokinetics and oxidative stress markers

FAQ

  • What is Pramipexole Dihydrochloride Monohydrate? Pramipexole Dihydrochloride Monohydrate, specifically its R(+) form, is an experimental neuroprotective drug being studied for its potential in treating Amyotrophic Lateral Sclerosis (ALS). It is believed to have antioxidant properties and can concentrate in the brain and mitochondria.
  • What is the main goal of these clinical trials? The main goal of these clinical trials is to assess whether R(+) Pramipexole can slow down the progression of ALS. Researchers are looking at how the drug affects the decline in ALS functional rating scales and other measures of disease progression.
  • How is the drug administered in these trials? In the trials, R(+) Pramipexole is administered orally. The dosage varies between studies, ranging from 20 mg three times a day to 100 mg three times a day.
  • What is ALS-FRSr? ALS-FRSr stands for ALS Functional Rating Scale (revised). It's a measure used to track the progression of ALS. In these trials, it's used as a primary outcome to assess how the drug affects the rate of decline in patients' functional abilities.
  • Are there any other measurements being taken in these trials? Yes, besides the ALS-FRSr, the trials are also measuring Forced Vital Capacity (FVC), hand dynamometry (grip strength), plasma levels of the drug, and biochemical markers of oxidative stress. These additional measurements help provide a more comprehensive understanding of the drug's effects and how it's processed in the body.

Ongoing Clinical Trials on Pramipexole Dihydrochloride Monohydrate

  • Study on Pramipexole for Patients with Resistant Obsessive-Compulsive Disorder (OCD)

    Recruiting

    2 1 1 1
    Investigated drugs:
    Portugal

  • Study on Pramipexole for Treating Restless Legs in Women with X-linked Adrenoleukodystrophy

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • Amyotrophic Lateral Sclerosis (ALS): A progressive nervous system disease that affects nerve cells in the brain and spinal cord, causing loss of muscle control.
  • Neuroprotective: Describing a substance that protects nerve cells against damage, degeneration, or impairment of function.
  • Antioxidant: A substance that can prevent or slow damage to cells caused by free radicals, unstable molecules that the body produces as a reaction to environmental and other pressures.
  • Mitochondria: Structures within cells that convert the energy from food into a form that cells can use.
  • ALS-FRSr: ALS Functional Rating Scale (revised), a tool used to measure the functional status of ALS patients.
  • Forced Vital Capacity (FVC): The total amount of air exhaled during a forced breath, used to assess lung function.
  • Hand dynamometry: A method to measure grip strength, often used to assess muscle function in ALS patients.
  • Oxidative stress: An imbalance between free radicals and antioxidants in the body, which can lead to cell and tissue damage.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics: The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.

References

  1. https://clinicaltrials.gov/study/NCT00596115
  2. https://clinicaltrials.gov/study/NCT00140218
  3. https://clinicaltrials.gov/study/NCT00600873